Roche (SWX:ROG) has won World Health Organization (WHO) prequalification for Actemra/RoActemra. Actemra/RoActemra is an anti-interleukin-6 receptor (aIL-6R) receptor antagonist with tocilizumab as an active substance. The prequalification will assist in low- and middle-income countries in procuring the therapy for patients on systemic corticosteroids who require supplemental oxygen or mechanical ventilation. Actemra/RoActemra is the twelfth medicine…